IntelGenX Pitch Deck (2017): 23-Slide Breakdown

The IntelGenX presentation from May 2017 outlines a strategic shift for a pharmaceutical company moving from pure R&D into a vertically integrated manufacturer. By leveraging their proprietary VersaFilm technology, the company targets the reformulation of existing drugs to improve patient outcomes and reduce side effects. The deck emphasizes a 'low risk' development model where partners fund R&D in exchange for marketing rights, while IntelGenX retains manufacturing control. With a newly completed 17,000 sq ft facility in Montreal and a proven track record of monetizing in-house developments…

Key takeaways

• The company operates under a low-risk development model where partners cover R&D expenses in exchange for exclusive marketing rights (Slide 7).
• IntelGenX retains all manufacturing rights for its products, ensuring a long-term revenue stream from production (Slide 7).
• The management team is highly technical, featuring over 20 employees with 7 holding Ph.D.s (Slide 4).
• A major milestone was the completion of a 17,000 sq ft state-of-the-art manufacturing facility in Montreal in Q1 2016 (Slide 16).
• Revenue grew significantly from US$1.7M in 2014 to US$5.2M in 2016 (Slide 19).
• The company successfully monetized its first in-house development, Forfivo XL, by selling U.S. revenue rights to SWK Holdings for US$6M (Slide 13).
• The VersaFilm technology is being applied to Loxapine for Schizophrenia, aiming to reduce pulmonary risks associated with traditional delivery (Slide 10).
• The business strategy relies on identifying high-value product opportunities and establishing strategic partnerships for commercialization (Slide 28).

Frequently asked questions

What is IntelGenX's core technology?

IntelGenX focuses on 'VersaFilm,' a proprietary oral thin film drug delivery technology. As shown on Slide 10, this technology allows for fast-acting oral dosages that can replace traditional delivery methods, potentially reducing side effects like pulmonary problems in specific medications like Loxapine.

How does IntelGenX generate revenue?

According to Slide 7, the company uses a multi-layered revenue model. They receive upfront and milestone payments for FDA submission, approval, and commercial launch. Additionally, they earn a share of net profits or royalties on sales and generate ongoing revenue by retaining exclusive manufacturing rights for the products they develop.

What is the company's current manufacturing capacity?

As of the 2017 presentation, IntelGenX had completed a 17,000 sq ft manufacturing and development facility in Montreal. Slide 16 notes that this facility became fully operational in Q1 2016 and includes high-capacity manufacturing and packaging equipment designed to lower costs and de-risk investments.

Is IntelGenX a pre-revenue startup?

No. Slide 19 shows that IntelGenX had established revenue streams prior to this presentation. They reported US$1.7M in 2014, US$5.1M in 2015, and US$5.2M in 2016. They also secured a US$6M non-dilutive payment from selling the U.S. revenue rights of Forfivo XL, as mentioned on Slide 13.

What is the 'Low Risk Development Model' mentioned in the deck?

This model, detailed on Slide 7, involves pharmaceutical partners paying for part or all of the R&D and regulatory costs. IntelGenX assesses the potential for successful development and determines the most prudent stage to seek a partner, thereby minimizing their own capital exposure during the high-risk clinical phases.

IntelGenX pitch deck: the facts

Company

IntelGenX

Year

2017

Stage

Public (TSX-V / OTCQX)

Slides

23

Sector

Pharmaceuticals / Drug Delivery

Deck type

Investor Presentation

Outcome

Active / Publicly Traded

Headquarters

Montreal, Canada

IntelGenX pitch deck PDF

The full IntelGenX deck is embedded on this page and can be read slide by slide in the browser — no download or account required. Each slide is covered in the breakdown above.

What the IntelGenx Technologies Corp. pitch deck was used for

This deck is a 23‑slide investor presentation dated May 1, 2017 for IntelGenx Technologies Corp., a TSX‑V/OTCQX‑listed oral drug delivery company focused on proprietary VersaFilm oral thin film products. It is explicitly tied to an April 5, 2017 Canadian preliminary short form prospectus and a Form S‑1 registration statement for an offering of 8% convertible unsecured subordinated debentures, aimed at funding capital expansion, clinical studies, product development and working capital. The company positions itself as transitioning from an R&D‑focused model to full‑scale manufacturing and commercialization while retaining manufacturing rights and partnering for commercialization. The deck highlights VersaFilm‑based programs such as Rizaport for migraines, a tadalafil oral film for erectile dysfunction, and a fast‑acting loxapine film for schizophrenia and bipolar I disorder, plus a low‑risk, partner‑driven development model.

Business model: IntelGenx is an oral drug delivery company that develops and manufactures pharmaceutical oral films based on its proprietary VersaFilm technology platform, focusing on improving existing approved drugs and developing novel oral film formulations.

Year

2017

Industry

Pharmaceuticals / Drug Delivery.

Round: Public convertible debenture offering under a Canadian short form prospectus with a parallel U.S. registration statement.

Raising: Targeted minimum CA$7,000,000 and maximum CA$10,000,000 aggregate principal amount of 8% convertible unsecured subordinated debentures at CA$1,000 per debenture, bearing 8% annual interest and maturing June 30, 2020.

Raised: CA$6.8 million aggregate principal amount of 8% convertible unsecured subordinated debentures completed in July 2017.

Headquarters: Saint-Laurent, Québec, Canada (corporate offices at 6420 Abrams, Ville Saint-Laurent, QC H4S 1Y2).

Use of funds as presented: Capital expansion, clinical studies, product development and general working capital requirements, as stated in the S‑1/A and the July 2017 completion announcement.

What happened after the IntelGenx Technologies Corp. deck

The specific 2017 fundraising associated with this deck culminated in a CA$6.8 million offering of 8% convertible debentures due June 30, 2020, used to support IntelGenx’s capital expansion, clinical programs, and product development as it progressed its VersaFilm oral thin film platform.

• IntelGenx filed a Canadian preliminary short form prospectus on April 5, 2017 and a related Form S‑1 registration statem
• On July 12, 2017, IntelGenx announced the completion of a CA$6.8 million convertible debenture offering, distributed und
• By 2018 and 2019, IntelGenx continued to position itself as a leading oral drug delivery company focused on VersaFilm or

What the IntelGenx Technologies Corp. deck got right

• Clear technology platform with concrete patient benefits. The deck leverages a clear, differentiated technology narrative around VersaFilm oral thin films, explicitly tying this to patient‑relevant benefits such as reduced side effects, improved bioavailability, faster response, lifecycle management of existing drugs, and discrete dosing without water, which provides a coherent and compelling value proposition.
• Capital‑efficient, partnership‑driven model. IntelGenx presents a capital‑efficient, low‑risk development model in which partners fund part or all of R&D, while IntelGenx retains manufacturing rights and earns milestones and royalties, aligning the financing story with a scalable, partnership‑driven business model.
• Multiple late‑stage products with defined regulatory milestones. The deck highlights multiple advanced programs—Rizaport with European marketing approval and regional partners, a tadalafil ED film with demonstrated bioequivalence and an Eli Lilly patent license, and a fast‑acting loxapine film—each with stated regulatory timelines, giving investors a portfolio of near‑ to mid‑term catalysts rather than a single binary event.
• Strong linkage between marketing deck and formal filings. By explicitly referencing the April 5, 2017 preliminary short form prospectus and U.S. S‑1 registration statement, the deck grounds its claims in formal securities filings, signaling regulatory discipline and giving investors a clear path to deeper due diligence on terms and risks.
• Investor‑friendly structure via yield‑bearing convertible debentures. The financing instrument—8% convertible unsecured subordinated debentures with a 2020 maturity—offers investors a defined yield and maturity profile plus equity upside through conversion, which can be attractive for public‑market investors evaluating risk‑reward versus straight equity.
• Compelling, patient‑oriented product narratives aligned with technology. Product messaging emphasizes practical differentiation, such as an orally disintegrating tadalafil film for convenience and discretion in ED, and a loxapine film aimed at reducing pulmonary issues and the risk of violence in acute agitation, which helps investors see how the technology translates into real‑world clinical and behavioral benefits.

What could have been stronger

• Optimistic regulatory timelines with limited risk disclosure in the slides themselves. The deck’s product timelines (e.g., Rizaport U.S. FDA submission in Q3 2017 with an early‑2018 PDUFA date; tadalafil film 505(b)(2) submission in Q2 2017 and expected U.S. approval in H1 2018) are presented without any explicit discussion of regulatory risk, prior interactions with FDA, or contingency plans if these timelines slip, leaving investors with optimistic dates but limited risk context.
• Limited quantitative detail on existing partnerships and milestone revenue. While Slide 7 outlines a partnership‑heavy model with milestones and shared profits, the extracted text does not provide concrete data such as the number of active partners, historical milestone inflows, or a pipeline‑by‑partner breakdown, making it difficult from the deck alone to quantify the robustness or diversification of partnership revenue.
• Manufacturing expansion story is under‑quantified in the deck extracts. The deck emphasizes that IntelGenx retains manufacturing rights and will derive manufacturing revenues, yet the partial text and associated filings do not show specific capacity metrics, capex plans, or margin profiles for manufacturing in the slides, which weakens the argument that the company is ready for large‑scale commercialization.
• Sparse financial disclosure in the presentation text we see. Although the notice to reader references the preliminary prospectus and S‑1/Registration Statement, the slides themselves (based on the OCR) include only high‑level forward‑looking statements and do not summarize key financials (e.g., revenue base, burn, or leverage), which means an investor relying on the slides alone would lack basic financial context.

How an investor would read this deck

What draws attention

• The 2017 deck is attached to a clearly defined financing instrument: 8% convertible unsecured subordinated debentures with a CA$7–10 million target size and 2020 maturity, giving investors near‑term yield plus equity‑linked upside.
• IntelGenx’s focus on oral thin films (VersaFilm) for lifecycle management (e.g., migraines, erectile dysfunction) and repurposing existing drugs means it is addressing known molecules and markets, potentially reducing development risk versus new chemical entities, while pursuing high‑value convenien
• The partnership‑centric model, where partners fund part or all of R&D and IntelGenx keeps manufacturing rights, could create a capital‑efficient path to multiple product launches if partnerships are numerous and well structured.
• Specific product opportunities—Rizaport with European approval and regional partners, tadalafil film leveraging an Eli Lilly patent, and loxapine for acute agitation—provide concrete programs with identifiable regulatory and commercial milestones.
• Filings and later communications describe IntelGenx as an established platform company (founded in 2003) with IP around VersaFilm and topical/oral film technologies, which is attractive for investors seeking platform leverage rather than single‑asset risk.

Risks that stand out

• Convertible unsecured subordinated debentures introduce leverage and potential future dilution, and as subordinated instruments they rank behind senior creditors in a liquidation scenario, which raises questions about downside protection for debenture and equity investors.
• The company’s strategy relies heavily on achieving regulatory approvals for film‑based versions of existing drugs, so any regulatory pushback (e.g., on bioequivalence, safety, or clinical endpoints) could delay or derail key programs like Rizaport and tadalafil films.
• A partnership‑driven commercialization model concentrates execution risk in partner performance; if partners delay launches, under‑resource marketing, or exit indications, IntelGenx’s royalty and manufacturing revenue projections may not materialize as implied.
• Oral thin film competition and the patent landscape could constrain IntelGenx’s ability to be first‑to‑file or to maintain differentiated positions in target indications, especially where branded films already exist and generic entrants face “high technology barriers” only in the near term.
• Given IntelGenx’s status as a smaller, single‑platform drug delivery company, access to capital markets and dependence on discrete financings (such as the 2017 debenture offering) pose ongoing financing risk if programs are delayed or markets become less receptive.

Questions this deck invites

• How did the company’s 2017 U.S. and Canadian regulatory timelines for Rizaport and the tadalafil film compare with actual outcomes (submission dates, PDUFA actions, approvals, or complete response letters), and what delays or setbacks occur
• What were IntelGenx’s revenue, operating loss, cash balance, and debt levels around the time of this offering, and how much runway did the CA$6.8 million convertible debenture raise ultimately provide given the planned use of proceeds for c
• How many active commercial and development partnerships did IntelGenx have in 2017, what were the key economic terms (upfronts, milestones, royalty rates), and how concentrated were these relationships in terms of counterparties and indicat
• What manufacturing capacity expansions were funded with the 2017 debenture proceeds, and what utilization, quality/regulatory status (e.g., FDA/EMA inspections), and gross margins has the facility achieved since then?
• Given IntelGenx’s history of prior financings (e.g., a roughly $3.5 million common stock offering in 2013) and subsequent capital raises, how has shareholder dilution evolved, and how have convertible instruments like the 2017 debentures af

What founders can take from the IntelGenx Technologies Corp. deck

• Attaching a deck directly to a live prospectus and registration statement, and explicitly instructing investors to read those documents, can enhance credibility by linking marketing claims to formal disclosures and regulatory filings.
• Positioning a specialty pharma platform around improving approved drugs via a proprietary delivery technology (VersaFilm oral films) allows a company to articulate a clear focus while leveraging known molecules and markets, which investors can more easily diligence.
• Explicitly outlining a low‑risk, partner‑funded development model—where partners pay R&D costs and IntelGenx retains manufacturing rights and shares in profits—can be persuasive to investors evaluating capital efficiency and downside protection.
• Highlighting region‑by‑region partnerships and regulatory milestones (e.g., European approval, territorial licensing deals, planned U.S. submissions) helps show concrete progress and near‑term catalysts rather than only long‑term vision.
• Using specific, patient‑centric product advantages (e.g., orally disintegrating films without water for ED, reduced pulmonary risk and violence risk in acute agitation) communicates practical differentiation beyond abstract technology claims.
• Aligning the use of proceeds in the financing (capital expansion, clinical studies, product development, working capital) with the deck’s narrative about transitioning from R&D to manufacturing and commercialization creates a coherent story of how new capital will drive the next phase.

IntelGenx Technologies Corp. pitch deck: common questions

What does IntelGenx do, according to the 2017 investor deck?

IntelGenx is a Canadian oral drug delivery company that develops and manufactures pharmaceutical oral films using its proprietary VersaFilm technology platform, with a focus on improving existing approved drugs and developing innovative film‑based dosage forms. The 2017 investor deck presents IntelGenx as a mature business monetizing oral thin film technology across multiple therapeutic areas, including migraines, erectile dysfunction, and neuropsychiatric indications.

What financing was IntelGenx raising around this May 2017 deck?

The May 1, 2017 investor presentation is tied to a Canadian preliminary short form prospectus dated April 5, 2017 and a U.S. Form S‑1 registration statement covering an offering of 8% convertible unsecured subordinated debentures due June 30, 2020. According to the S‑1/A, the company was offering a minimum of CA$7,000,000 and a maximum of CA$10,000,000 of these debentures, with proceeds intended for capital expansion, clinical studies, product development and general working capital.

Which products and pipelines does the 2017 IntelGenx deck highlight and what timelines does it claim?

Rizaport VersaFilm for migraines had received European marketing approval in November 2015 and was partnered with RedHill Biopharma; the deck notes definitive agreements with Grupo Juste for Spain and other territories (July 2016) and Pharmatronic for South Korea (December 2016), and indicates a planned U.S. FDA submission in Q3 2017 with a PDUFA date expected in early 2018. The tadalafil VersaFilm product for erectile dysfunction is described as an orally disintegrating film containing tadalafil (Cialis) with demonstrated bioequivalence to Cialis, licensed under an Eli Lilly patent, with a planned 505(b)(2) submission in Q2 2017 and expected U.S. approval in H1 2018. The loxapine VersaFilm

How does IntelGenx’s business model work according to the deck?

The deck emphasizes a partnership‑driven model where IntelGenx grants commercialization rights to partners in exchange for upfront and milestone payments plus a share of partner net profits or royalties, while IntelGenx retains manufacturing rights and related revenues. It highlights that partners often fund part or all of R&D expenses, and that payments are triggered at milestones such as FDA submission, FDA approval, commercial launch, and sales targets. This structure is presented as lowering development risk while preserving long‑term manufacturing income.

What were the key terms of the 2017 IntelGenx convertible debenture offering linked to this deck?

According to the S‑1/A, the convertible unsecured subordinated debentures being offered in 2017 carried an 8% annual interest rate, payable semi‑annually on June 30 and December 31, with a maturity date of June 30, 2020. The debentures were to be issued at CA$1,000 per debenture, with total issue costs estimated around CA$350,000 and a sales commission of 6% of gross proceeds; the specific conversion price and final size of the offering were to be determined in the context of the market prior to filing the final short form prospectus.

Sources

Funding and outcome facts on this page were researched on 2026-08-22 from the pages below.

• IntelGenx Technologies Corp. (Form: S-1/A, Received: 05/12/2017 16:40:33)
• IntelGenx Technologies Corp. (Form: S-1/A, Received - EDGAR Online
• IntelGenx Technologies Corp. Form 10-K Annual Report Filed 2018-03-29
• IntelGenx Technologies Corp.: Form 10-K - Filed by newsfilecorp.com
• IntelGenx March 13, 2017 Investor Presentation
• IntelGenx Corp. Announces Public Offering Of... - BioSpace
• IntelGenx Announces Issuance of Second U.S. Patent for Topical Oral Film Technology
• IntelGenx Receives USPTO Notice of Allowance for Oral Film...

IntelGenX pitch deck slides

What each slide of the IntelGenX pitch deck says

Slide 1

Innovative Drug Delivery Solutions Investor Presentation May 1, 2017 WE MAKE APPROVED DRUGS BETTER A preliminary short form prospectus containing important information relating to the securities described in this document has been filed with the securities regulatory authorities in British Columbia, Alberta, Manitoba, Ontario and Québec. A copy of the preliminary short form prospectus, and any amendment, is required to be delivered with this document. The preliminary short form prospectus is still subject to completion. There will not be any sale or any acceptance of an offer to buy the securities until a receipt for the final short form prospectus has been issued. This document does not pr…

Slide 2

Notice to Reader This presentation has been prepared by us and should be read in conjunction with the Canadian preliminary short form prospectus of IntelGenx Technologies Corp. ('IntelGenx", 'we", "us" or "our') dated April 5, 2017 and available on SEDAR at www.sedar.com, including the documents incorporated by reference therein (the "Preliminary Prospectus") o the Form S-1 registration statement under the United States Securities Act of 1933, as amended, of IntelGenx dated April 5, 2017 and available on EDGAR at www.edgar.com (the "Registration Statement'). Before you invest, you should read the registration statement and other documents the Corporation has filed with the SEC for more comp…

Slide 3

Company Snapshot RN - i * IntelGenx Corp. Founded 2003 + TSX-V (IGX) CAD$0.92 + OTCQX (IGXT)™ US$0.70 . » Market Capitalization (1) CAD$65M © «Shares Issued 65.4M — + Shares Fully Diluted 70.8M » Insider Beneficial Ownership 18.7% al i \ oi + Cash/Short Term Investments CAD$6M (As of Dec 31, 2016) Analyst Coverage Ty Firm Analyst pgp Oe H.C. Wainwright Swayampakula Ramakanth 9 Singular Research Greg Eisen wets = Rigapert "40, 1) As at April 28, 2017 IntciGen, - IntelGen, me

Slide 4

Over 20 Employees, including 7 with Ph.D.’s BN Horst G. Zerbe, Ph.D. Andre Godin, cPA, cA John Durham, B. sc. Chairman, President & CEO Executive VP, CFO VP, Manufacturing Operations « 30+ years drug delivery / 2 youn biotech/pharma + 20+ years experience in pharma experience NCHS expenctics pharmaceutical ? + Member of the Canadian manufacturing, quality Holds over J0fpaterisin dig Chartered Professional management, product delivery and numerous Accountants and the Ht : pment scientific publications. Canadian Institute of + Previously employed at 3M; Chartered Accountants + Held executive positions with ; : § several Canadian and U.S. Smartrix Technologies and + Capital markets experience…

Slide 5

Advantages of Oral Thin Film Delivery We are focused on areas where oral films are particularly well-suited: Develop and commercialize products that provide therapeutic advantages to patients leveraging oral films, such as: + Reduced side effects + Improved bio-availability il « Response time versus existing drugs - Lifecycle management - Repurpose existing drugs for new indications using oral films m d - Developing generic drugs where high technology barriers to entry exist in reproducing branded films with a focus on being the first-to-file IntelGen,

Slide 6

Clearly Defined BD Strategy Balancing Risks and Opportunities for an Optimized Portfolio IntelGenx Future Focus Deal Value Low (lifec le Mgmt ® Low O Medium (Patient Bonéfits OJ High Overall a Risk OFTF Generics High Slow Time to Market Fast IntelGen,

Slide 7

A Low Risk Development Model IntelGenx grants partners certain exclusive rights to market and sell its products in exchange for upfront and milestone payments, together with a share of the Partner's net profits or a royalty on net product sales. IntelGenx retains manufacturing rights for its products. Its revenue stream will also include manufacturing revenues. » Payments are received as the contracted services are performed or when certain milestones are achieved: * FDA submission, « FDA approval, * Commercial launch, « Annual net sales target, etc. » Partnerships are also established with respect to other products in development » Pharmaceutical partners pay for part or all of the R&D exp…

Slide 8

Rigaport 7 For Migraines VersaFilm Leverages VersaFilm™ Technology w » European Marketing Approval — November 2015 » Co-development partnership with RedHill Biopharma « Definitive agreement signed July 2016 with Grupo Juste for Spain & additional territories « Definitive agreement signed December 2016 with Pharmatronic for South Korea « Actively pursuing several opportunities to open new markets - negotiations with future commercialization partners ongoing * Planned USA submission to FDA Q3 2017 » PDUFA date expected in early 2018 IntelGen, o IntelGen, B

Slide 9

For Erectile Dysfunction VersaFilm » IntelGenx secured exclusive license for oral film from Eli Lilly for Tadalafil ED dosing patent '166 » Accelerates our partnering of this product for commercializing Tadalafil in the U.S. + Containing Tadalafil (Cialis®- Eli Lilly), a leading molecule in the ED market - Demonstrated bioequivalence to Cialis® * Orally disintegrating films without need for water provide unprecedented patient convenience and a discrete dosing alternative « 505(b)(2) USA FDA submission in Q2 2017 * Expected USA approval H1 2018 IntelGen, =

Slide 10

For Schizophrenia & versafim - Bipolar 1 Disorder » The first oral thin film using IntelGenx proprietary drug delivery technology, VersaFilm™ for treatment of schizophrenia & bipolar 1 disorder » Fast-acting loxapine oral dosage — to treat acute agitation and anxiety in noninstitutionalized patients with schizophrenia & bipolar 1 disorder VersaFilm - f & X{('/)(),z e * Reduces risk of pulmonary problems and potential risk of violence and injury to patients and others IntelGen,

Slide text above is read directly from the IntelGenX deck PDF embedded on this page.

Related fundraising guides (24)

• Cove.Tool Pitch Deck Teardown: A Masterclass in Visualizing Efficiency Gains
• EVERY Pitch Deck Teardown: A $175M Masterclass in Precision Fermentation Storytelling
• Alcatraz AI Pitch Deck Teardown: Leveraging Apple FaceID Pedigree for Enterprise Security
• Hang Pitch Deck Teardown: A $16M Series A Masterclass in Web3 Enterprise Utility
• Beam Dental Pitch Deck Teardown: A Masterclass in Structural Cost Advantage
• Ideon Technologies Pitch Deck Teardown: Using Muon Tomography to De-Risk Mining Exploration
• Circ Pitch Deck Teardown: Solving the Polycotton Recycling Gap with Hydrothermal Tech
• Trash Warrior Pitch Deck Teardown: Disrupting the $56B Commercial Waste Collection Market
• Dame Pitch Deck Teardown: A $7M Series A Masterclass in Normalizing Stigmatized Consumer Goods
• Kinnu Pitch Deck Teardown: A Masterclass in Social Proof and Product-Led Growth
• Examedi Pitch Deck Teardown: A Lean Vision for Latin American Healthcare Logistics
• Amogy Pitch Deck Teardown: Solving the Energy Density Gap for Heavy-Duty Mobility
• Hervé Pitch Deck Teardown: Scaling Luxury Cannabis Edibles Through Proprietary Hardware
• Brag House Pitch Deck Teardown: Targeting the Casual Collegiate Esports Market
• Innovafeed Pitch Deck Teardown: A $250M Masterclass in Industrial Scale and Strategic Partnerships
• Claira Pitch Deck Teardown: Solving the Legal Logic Gap in Financial Contracts
• Curio.io Pitch Deck Teardown: Selling High-Engagement Audio Journalism
• EcoLocked Pitch Deck Teardown: Decarbonizing Construction via Biochar Admixes
• Aeris Health Pitch Deck Teardown: A Masterclass in Hardware Traction and COVID-Era Pivoting
• Florence Pitch Deck Teardown: Scaling a Healthcare Staffing Marketplace to £9bn Market Potential
• Arist Pitch Deck Teardown: The $12M Series A Memo Strategy for Micro-Learning
• Hintsa Pitch Deck Teardown: A $5.2M Masterclass in High-Performance Wellness Branding
• Bravo Sierra Pitch Deck Teardown: Leveraging Military Community for CPG Scale
• Layla Pitch Deck Teardown: A $3M Seed Round Built on AI-Powered Travel Discovery

Decks from the same year (1)

• 2017 pitch deck examples

Decks from the same region (1)

• Canadian pitch deck examples

Browse companies alphabetically (1)

• Pitch decks from companies starting with I

More pitch deck teardowns (16)

• Instaparty Pitch Deck Teardown: A Pre-Launch Marketplace for Nightlife Bookings
• Instructure Pitch Deck Teardown: Scaling the Modern Learning Management System
• Instructure Pitch Deck Teardown: Scaling EdTech Through Multi-Year Contract Visibility
• Instructure Pitch Deck Teardown: Scaling EdTech into Enterprise Talent Management
• Instructure Pitch Deck Teardown: Scaling EdTech Through Efficiency and Global Expansion
• Instructure Pitch Deck Teardown: A Masterclass in Post-IPO Investor Relations Transparency
• Intech Harness Pitch Deck Teardown: Solving Irrigation Inefficiency with Patented IoT Hardware
• Intelen Pitch Deck Teardown: Gamifying Energy Efficiency for Smart Grids
• IntelGenx Pitch Deck Teardown: Leveraging Oral Thin Film Tech for a $19B Drug Delivery Market
• Intercom Pitch Deck Teardown: A Masterclass in Early-Stage Product Focus
• Intercom Pitch Deck Breakdown: How to Sell a Category-Defining Vision
• Intercom Pitch Deck Teardown: A Lean, Problem-Focused Seed Round Pitch
• Intergalactic Enterprises Pitch Deck Teardown: A Massive Vision for Global Golf Entertainment
• InternSource Pitch Deck Teardown: A Badging-Led Approach to the Internship Market
• Interpace Diagnostics Pitch Deck Teardown: Validating Molecular Cancer Risk Classifiers
• Intersailclub Pitch Deck Teardown: A Niche Travel Marketplace Betting on Cabin-Level Booking

Recently published pitch deck teardowns (12)

• Liberare Pitch Deck Teardown: A $1M Pre-Seed Strategy for Adaptive Fashion
• Liminal Pitch Deck Teardown: Quantifying the ROI of Ultrasound Battery Inspection
• Lighthouse Labs Pitch Deck Teardown: Navigating the Fragmentation of the Metaverse
• Lindus Health Pitch Deck Teardown: A Product-First Approach to Clinical Trials
• LiquidStack Pitch Deck Teardown: Riding the Generative AI Hardware Inflection Point
• Lirvana Labs Pitch Deck Teardown: A $5.3M Seed Round Built on Social Impact and Pedigree
• Little Journey Pitch Deck Teardown: Quantifying the Financial Cost of Pediatric Patient Anxiety
• LogRock Pitch Deck Teardown: A $3.5M Seed Masterclass in Niche Compliance Automation
• LTV.ai Pitch Deck Teardown: A $5.2M Series A Case Study in AI-Native Marketing
• Lumiform Pitch Deck Teardown: A Product-First Masterclass in Workflow Automation
• Lunio Pitch Deck Teardown: A $15M Series A Masterclass in Cybersecurity Pedigree
• LucidLink Pitch Deck Teardown: Solving the Latency Gap in Remote Creative Collaboration

Fundraising library · Pitch deck examples · Investor directory · Founder database